作者@article {Lavole1902066 = {Lavole, Armelle Greillier,劳伦和Mazi {\ ' e} res,朱利安和莫内,伊莎贝尔和Kiakouama-Maleka Lize Quantin,泽维尔斯帕诺,让菲利普和莉娜,Herve Fraisse,菲利普和Janicot,亨利和Audigier-Valette,她和Langlais,亚历山德拉和莫林,弗兰克和梅金森,一线卡铂+培美曲塞联合培美曲塞维持治疗晚期非鳞状细胞肺癌的hiv阳性患者:II期IFCT-1001 CHIVA试验}，volume = {56}， number = {2}， eloc- id = {1902066}， year = {2020}， doi = {10.1183/13993003.02066-2019}， publisher ={欧洲呼吸学会}，abstract = {188bet官网地址HIV感染是肺癌试验的排除标准。这项多中心II期临床试验旨在评估一线卡铂+培美曲塞(CaP) +培美曲塞(P)维持治疗在晚期非鳞状非小细胞肺癌(NS-NSCLC)患者中的可行性、有效性和安全性。东方肿瘤合作治疗组表现状态<=2的患者行4个周期CaP后进行p维持治疗。主要目标是12周后疾病控制率(DCR) >=30\%。在纳入的61例PLHIV患者中，49例(80 %)表现状态为0{{textendash}1, 19例(31 %)有脑转移。CD4淋巴细胞计数中位数为418个细胞{\周期中心}{\textmu}L-1 (range 18{\周期中心}{\textmu}L-1 (range 18{\周期中心}{\textmu}L-1(1{\周期中心}{\textmu}L-1(1{\周期中心}{\textmu}L-1(1{\周期中心}{\textmu}L-1);48例(80%)患者病毒学得到控制。38例(62\%)患者实现了4个周期的诱导，31例(51\%)开始p -维持(中位数为4.1个周期(范围1{textendash}19))。12周的DCR为50.8% \% (95\% CI 38.3{\textendash}63.4)，部分缓解率为21.3% \%。 Median progression-free survival and overall survival were 3.5 (95\% CI 2.7{\textendash}4.4) and 7.6 months (5.7{\textendash}12.8), respectively. Patients with a performance status of 0{\textendash}1 had the longest median progression-free survival (4.3 months, 95\% CI 3.1{\textendash}5.2) and overall survival (11.9 months, 95\% CI 6.4{\textendash}14.3). During induction, CaP doublet was well tolerated apart from grade 3{\textendash}4 haematological toxicities (neutropenia 53.8\%; thrombocytopenia 35.0\%; anaemia 30.0\%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced.In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.In this first clinical trial dedicated to people living with HIV and advanced non-squamous non-small cell lung cancer, first-line 4-cycle carboplatin plus pemetrexed followed by pemetrexed maintenance chemotherapy was effective and reasonably well-tolerated https://bit.ly/2xAqeEl}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/56/2/1902066}, eprint = {//www.qdcxjkg.com/content/56/2/1902066.full.pdf}, journal = {European Respiratory Journal} }